白雲山(600332.SH):子公司獲得變更後的《藥品生產許可證》
格隆匯7月15日丨白雲山(600332.SH)公吿,2021年7月14日,公司子公司廣州白雲山奇星藥業有限公司(“奇星藥業”)收到省藥監局頒發的本次申請變更後的《藥品生產許可證》,省藥監局批准奇星藥業《藥品生產許可證》生產地址及生產範圍的變更事項。
本次變更《藥品生產許可證》的內容是奇星藥業新增委託廣州粵華製藥有限公司生產清熱定驚散(國藥準字Z44023246),受託生產地址為廣州市白雲區廣花三路438號,其餘內容不變。
本次取得變更後的《藥品生產許可證》,有利於奇星藥業多渠道、多品種生產,有助於其擴大銷售市場及消費人羣,帶來更高效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.